963 related articles for article (PubMed ID: 29166140)
1. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes.
Gharbiya M; Giustolisi R; Marchiori J; Bruscolini A; Mallone F; Fameli V; Nebbioso M; Abdolrahimzadeh S
Curr Eye Res; 2018 Mar; 43(3):391-396. PubMed ID: 29166140
[TBL] [Abstract][Full Text] [Related]
2. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration.
Yun C; Oh J; Ahn J; Hwang SY; Lee B; Kim SW; Huh K
Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1693-702. PubMed ID: 26781585
[TBL] [Abstract][Full Text] [Related]
3. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
Park DH; Sun HJ; Lee SJ
Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
[TBL] [Abstract][Full Text] [Related]
4. Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus Aflibercept.
Gharbiya M; Cruciani F; Mariotti C; Grandinetti F; Marenco M; Cacace V
J Ocul Pharmacol Ther; 2015; 31(6):357-62. PubMed ID: 26133059
[TBL] [Abstract][Full Text] [Related]
5. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
Steinle NC; Du W; Gibson A; Saroj N
Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration.
Abdin AD; Suffo S; Asi F; Langenbucher A; Seitz B
Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1671-1677. PubMed ID: 31144055
[TBL] [Abstract][Full Text] [Related]
8. Indocyanine green angiography findings in patients with neovascular age-related macular degeneration refractory to ranibizumab switched to aflibercept.
Calvo-Gonzalez C; Reche-Frutos J; Fernández-Vigo JI; Donate-López J; Serrano-García I; Fernández-Pérez C
Int Ophthalmol; 2019 Nov; 39(11):2441-2448. PubMed ID: 30767090
[TBL] [Abstract][Full Text] [Related]
9. Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study.
Kim JH; Lee TG; Chang YS; Kim CG; Cho SW
Br J Ophthalmol; 2016 Dec; 100(12):1634-1639. PubMed ID: 26951770
[TBL] [Abstract][Full Text] [Related]
10. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration.
Au A; Parikh VS; Singh RP; Ehlers JP; Yuan A; Rachitskaya AV; Sears JE; Srivastava SK; Kaiser PK; Schachat AP; Martin DF; Modi Y
Br J Ophthalmol; 2017 Jul; 101(7):970-975. PubMed ID: 27913442
[TBL] [Abstract][Full Text] [Related]
11. Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: Ranibizumab versus aflibercept.
Kaya F
J Fr Ophtalmol; 2017 Dec; 40(10):832-838. PubMed ID: 29113742
[TBL] [Abstract][Full Text] [Related]
12. Short-term effects of anti-vascular endothelial growth factor on peripapillary choroid and choriocapillaris in eyes with neovascular age-related macular degeneration.
Lee B; Yoo G; Yun C; Oh J
Graefes Arch Clin Exp Ophthalmol; 2019 Oct; 257(10):2163-2172. PubMed ID: 31367847
[TBL] [Abstract][Full Text] [Related]
13. Change in choroidal thickness after intravitreal aflibercept in pretreated and treatment-naive eyes for neovascular age-related macular degeneration.
Mazaraki K; Fassnacht-Riederle H; Blum R; Becker M; Michels S
Br J Ophthalmol; 2015 Oct; 99(10):1341-4. PubMed ID: 25877895
[TBL] [Abstract][Full Text] [Related]
14. Early Changes of Retinal Morphology in Therapy of Neovascular Age-Related Macular Degeneration with Three Commonly Used Anti-VEGF Agents.
Enders P; Sitnilska V; Altay L; Fauser S
Ophthalmologica; 2018; 239(1):45-51. PubMed ID: 28950272
[TBL] [Abstract][Full Text] [Related]
15. Subfoveal Choroidal Thickness in Eyes with Neovascular Age-Related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
Kanadani TCM; Veloso CE; Nehemy MB
Ophthalmologica; 2018; 240(4):200-207. PubMed ID: 29768266
[TBL] [Abstract][Full Text] [Related]
16. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
Jørstad ØK; Faber RT; Moe MC
Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
[TBL] [Abstract][Full Text] [Related]
17. MACULAR ATROPHY AND MACULAR MORPHOLOGY IN AFLIBERCEPT-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Kuroda Y; Yamashiro K; Ooto S; Tamura H; Oishi A; Nakanishi H; Miyata M; Hata M; Takahashi A; Wakazono T; Yoshimura N; Tsujikawa A
Retina; 2018 Sep; 38(9):1743-1750. PubMed ID: 28691937
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of switching to aflibercept for treatment-resistant neovascular age-related macular degeneration.
Spooner K; Hong T; Nair R; Chow NCC; Broadhead GK; Wijeyakumar W; Chang AA
Acta Ophthalmol; 2019 Aug; 97(5):e706-e712. PubMed ID: 30740921
[TBL] [Abstract][Full Text] [Related]
19. Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies.
Lanzetta P; Cruess AF; Cohen SY; Slakter JS; Katz T; Sowade O; Zeitz O; Ahlers C; Mitchell P
Acta Ophthalmol; 2018 Dec; 96(8):e911-e918. PubMed ID: 29659183
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization.
Van Lancker L; Petrarca R; Moutsouris K; Masaoutis P; Kampougeris G
Eur J Ophthalmol; 2017 May; 27(3):342-345. PubMed ID: 27739561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
